HK1113927A1 - Substituted triazole derivatives as oxytocin antagonists - Google Patents

Substituted triazole derivatives as oxytocin antagonists

Info

Publication number
HK1113927A1
HK1113927A1 HK08103169.1A HK08103169A HK1113927A1 HK 1113927 A1 HK1113927 A1 HK 1113927A1 HK 08103169 A HK08103169 A HK 08103169A HK 1113927 A1 HK1113927 A1 HK 1113927A1
Authority
HK
Hong Kong
Prior art keywords
triazole derivatives
substituted triazole
oxytocin antagonists
oxytocin
antagonists
Prior art date
Application number
HK08103169.1A
Other languages
English (en)
Inventor
Alan Daniel Brown
Andrew Antony Calabrese
David Ellis
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of HK1113927A1 publication Critical patent/HK1113927A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK08103169.1A 2005-01-20 2008-03-19 Substituted triazole derivatives as oxytocin antagonists HK1113927A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0501190.3A GB0501190D0 (en) 2005-01-20 2005-01-20 Novel pharmaceuticals
PCT/IB2006/000118 WO2006077496A1 (en) 2005-01-20 2006-01-11 Substituted triazole derivatives as oxytocin antagonists

Publications (1)

Publication Number Publication Date
HK1113927A1 true HK1113927A1 (en) 2008-10-17

Family

ID=34259404

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08103169.1A HK1113927A1 (en) 2005-01-20 2008-03-19 Substituted triazole derivatives as oxytocin antagonists

Country Status (32)

Country Link
US (5) US7557131B2 (da)
EP (1) EP1841758B1 (da)
JP (1) JP4124805B1 (da)
KR (1) KR100936854B1 (da)
CN (1) CN101107243B (da)
AP (1) AP2007004047A0 (da)
AR (1) AR055303A1 (da)
AT (1) ATE449091T1 (da)
AU (1) AU2006207300B2 (da)
BR (1) BRPI0606463A2 (da)
CA (1) CA2595569C (da)
CR (1) CR9219A (da)
DE (1) DE602006010508D1 (da)
DK (1) DK1841758T3 (da)
DO (1) DOP2006000014A (da)
EA (1) EA200701328A1 (da)
ES (1) ES2334517T3 (da)
GB (1) GB0501190D0 (da)
GT (1) GT200600024A (da)
HK (1) HK1113927A1 (da)
IL (1) IL184148A (da)
MA (1) MA29160B1 (da)
MX (1) MX2007008757A (da)
NL (1) NL1030961C2 (da)
NO (1) NO338420B1 (da)
PA (1) PA8660401A1 (da)
PE (1) PE20060875A1 (da)
TN (1) TNSN07275A1 (da)
TW (1) TW200637847A (da)
UY (1) UY29339A1 (da)
WO (1) WO2006077496A1 (da)
ZA (1) ZA200705718B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06284516A (ja) * 1993-03-31 1994-10-07 Mitsubishi Electric Corp 電気車制御装置
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
JP2008545760A (ja) * 2005-06-09 2008-12-18 メルク フロスト カナダ リミテツド ステアロイル−コエンザイムaデルタ−9デサチュラーゼのインヒビターとしてのアザシクロヘキサン誘導体
GB0607196D0 (en) * 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
JP2009539884A (ja) * 2006-06-12 2009-11-19 メルク フロスト カナダ リミテツド ステアロイル−コエンザイムaデルタ−9デサチュラーゼのインヒビターとしてのアゼチジン誘導体
JP2009539885A (ja) * 2006-06-13 2009-11-19 メルク フロスト カナダ リミテツド ステアロイルコエンザイムaデルタ−9デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体
EP2141994A4 (en) * 2007-04-26 2011-05-18 Avalon Pharmaceuticals POLYCYCLIC COMPOUNDS AND USES THEREOF
MX2010007660A (es) 2008-01-31 2010-08-10 Sanofi Aventis Indol-3-carboxamidas ciclicas, su preparacion y su uso como productos farmaceuticos.
PT2240482E (pt) 2008-01-31 2013-09-06 Sanofi Sa Azaindole-3-carboxamidas cíclicas, sua preparação e sua utilização como fármacos
HUE034409T2 (en) * 2012-07-16 2018-02-28 Fibrogen Inc Process for the preparation of isoquinoline compounds
WO2016014975A2 (en) 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
WO2018091687A1 (en) 2016-11-18 2018-05-24 Integrative Research Laboratories Sweden Ab Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
WO2018113694A1 (zh) 2016-12-21 2018-06-28 江苏恒瑞医药股份有限公司 稠环基氮杂环丁基三唑类衍生物、其制备方法及其在医药上的应用
JP2020504109A (ja) * 2016-12-28 2020-02-06 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. アザビシクロ置換トリアゾール誘導体、その調製方法、及びその医薬用途
WO2019242646A1 (zh) * 2018-06-20 2019-12-26 江苏恒瑞医药股份有限公司 催产素受体抑制剂的晶型及其制备方法
CN111094272B (zh) * 2018-06-20 2022-05-27 江苏恒瑞医药股份有限公司 一种otr抑制剂的可药用盐、晶型及制备方法
WO2020001460A1 (zh) * 2018-06-27 2020-01-02 江苏恒瑞医药股份有限公司 氮杂双环基取代的三唑类衍生物的可药用盐、晶型及制备方法
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法
CN113582818B (zh) * 2021-08-30 2023-08-01 上海日异生物科技有限公司 一种3-卤-2-烷基苯酚的合成方法
WO2023156386A2 (en) * 2022-02-16 2023-08-24 Duke Street Bio Limited Pharmaceutical compound
CN114805161B (zh) * 2022-06-14 2023-08-25 南通华祥医药科技有限公司 一种3-氟丫丁啶盐酸盐的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554276A (en) 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US5053411A (en) 1989-04-20 1991-10-01 Anaquest, Inc. N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides and pharmaceutical compositions and methods employing such compounds
DE4124942A1 (de) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0891356A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0904076A1 (en) 1996-04-03 1999-03-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU715658B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000509371A (ja) 1996-04-03 2000-07-25 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
JP2002511054A (ja) 1996-12-30 2002-04-09 メルク エンド カンパニー インコーポレーテッド ファルネシル蛋白トランスフェラーゼ阻害薬
AU759825B2 (en) 1997-12-16 2003-05-01 Pfizer Products Inc. Combination effective for the treatment of impotence
AU763976B2 (en) 1999-07-23 2003-08-07 Shionogi & Co., Ltd. Th2 differentiation inhibitors
SI1224174T1 (en) 1999-10-15 2003-12-31 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
AU779426B2 (en) 1999-11-15 2005-01-27 Janssen Pharmaceutica N.V. Triazoles as farnesyl transferase inhibitors
WO2001076582A1 (fr) 2000-04-05 2001-10-18 Shionogi & Co., Ltd. Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci
US20030216385A1 (en) 2000-05-19 2003-11-20 Takahiko Tobe Triazole derivatives
EP1293503A4 (en) * 2000-05-19 2008-04-02 Astellas Pharma Inc Triazole derivatives
EP1432687A2 (en) 2001-10-03 2004-06-30 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0208579D0 (en) 2002-04-13 2002-05-22 British Biotech Pharm Antibacterial agents
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
BRPI0414663A (pt) 2003-09-22 2006-11-21 Pfizer derivados triazol substituìdos como antagonistas de oxitocina
JP4698604B2 (ja) 2003-12-22 2011-06-08 ファイザー・インク バソプレシン・アンタゴニストとしてのトリアゾール誘導体
WO2005082866A2 (en) * 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
US20070225333A1 (en) 2004-04-28 2007-09-27 Bryans Justin S 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists

Also Published As

Publication number Publication date
US10150752B2 (en) 2018-12-11
EP1841758A1 (en) 2007-10-10
US20150322042A1 (en) 2015-11-12
US8207198B2 (en) 2012-06-26
EA200701328A1 (ru) 2007-12-28
KR20070091023A (ko) 2007-09-06
PE20060875A1 (es) 2006-09-04
UY29339A1 (es) 2006-08-31
ZA200705718B (en) 2008-08-27
CN101107243A (zh) 2008-01-16
WO2006077496A1 (en) 2006-07-27
PA8660401A1 (es) 2006-09-08
DOP2006000014A (es) 2006-07-31
US20130137671A1 (en) 2013-05-30
ES2334517T3 (es) 2010-03-11
TNSN07275A1 (fr) 2008-12-31
AU2006207300A1 (en) 2006-07-27
MA29160B1 (fr) 2008-01-02
NL1030961A1 (nl) 2006-07-21
NO20074177L (no) 2007-10-16
ATE449091T1 (de) 2009-12-15
CR9219A (es) 2007-07-24
KR100936854B1 (ko) 2010-01-14
AR055303A1 (es) 2007-08-15
TW200637847A (en) 2006-11-01
US20170114040A1 (en) 2017-04-27
US9394278B2 (en) 2016-07-19
AP2007004047A0 (en) 2007-06-30
NO338420B1 (no) 2016-08-15
GB0501190D0 (en) 2005-03-02
JP4124805B1 (ja) 2008-07-23
NL1030961C2 (nl) 2007-01-12
JP2008528476A (ja) 2008-07-31
CA2595569C (en) 2010-07-20
US20060160786A1 (en) 2006-07-20
US7557131B2 (en) 2009-07-07
IL184148A0 (en) 2007-10-31
BRPI0606463A2 (pt) 2009-06-30
GT200600024A (es) 2006-08-23
EP1841758B1 (en) 2009-11-18
DE602006010508D1 (de) 2009-12-31
AU2006207300B2 (en) 2011-03-03
CA2595569A1 (en) 2006-07-27
MX2007008757A (es) 2008-03-10
US9023872B2 (en) 2015-05-05
CN101107243B (zh) 2010-11-24
DK1841758T3 (da) 2010-01-18
US20090253674A1 (en) 2009-10-08
IL184148A (en) 2013-06-27

Similar Documents

Publication Publication Date Title
IL184148A0 (en) Substituted triazole derivatives as oxytocin antagonists
HK1114839A1 (en) Hsp90-inhibiting triazole derivatives
IL190450A0 (en) Substituted pyrazole compounds
EP1847531A4 (en) PYRAZOLE DERIVATIVE
ZA200803811B (en) Neuropolin antagonists
ZA200709994B (en) Neurotherapeutic Azole Compounds
SI1919907T1 (sl) Heterocikliäśna spojina
ZA200709051B (en) Heterocyclic compound
HK1129305A1 (zh) 取代的 -氨基-吡咯並三嗪衍生物
HK1095822A1 (en) Triazole derivatives as vasopressin antagonists
EP1871766A4 (en) TRIAZONE DERIVATIVES WITH ANTIPILY EFFECT
HK1123038A1 (en) Heterocyclic compounds
ZA200806358B (en) Triazole Derivatives
HK1121755A1 (en) New compounds iii
PL1870409T3 (pl) Związki benzimidazolowe
IL184841A0 (en) Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives
IL179912A0 (en) Substituted diketopiperazines as oxytocin antagonists
EP1951705A4 (en) NEW ANTIFUNGAL TRIAZOLE DERIVATIVES
ZA200802339B (en) Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
IL184559A0 (en) Imidazole derivatives
ZA200800142B (en) Heterocyclic compound
ZA200802786B (en) Substituted pyrazole compounds
ZA200803017B (en) Heterocyclic compounds
GB0415110D0 (en) Substituted triazole derivatives as oxytocin antagonists
GB0508681D0 (en) Antagonist